 Adamis Pharmaceuticals Corporation NASDAQ: ADMP has resubmitted a marketing application to the FDA for Zimhi, a naloxone injection product candidate intended to treat opioid overdose. Based on FDA feedback received during our Type A meeting in April, we have resubmitted our NDA for ZIMHI, which I am confident fully addresses the issues raised in the Complete Response Letter, said President and CEO Dr. Dennis J. 